Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 5.3% – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s stock price dropped 5.3% during trading on Friday . The company traded as low as $37.26 and last traded at $36.9150. Approximately 157,405 shares changed hands during mid-day trading, a decline of 27% from the average session volume of 216,524 shares. The stock had previously closed at $39.00.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Needham & Company LLC assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, August 21st. They issued a “buy” rating and a $56.00 price objective for the company. JonesTrading began coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They issued a “buy” rating and a $55.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Sensei Biotherapeutics in a research report on Tuesday, August 11th. Oppenheimer started coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target for the company. Finally, Loop Capital set a $50.00 price target on Sensei Biotherapeutics in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Trading Down 4.0%

The firm has a 50 day simple moving average of $31.34. The company has a market cap of $967.45 million, a price-to-earnings ratio of -0.26 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last released its earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Brian C. Stephenson purchased 5,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were purchased at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the purchase, the chief financial officer directly owned 46,688 shares of the company’s stock, valued at approximately $1,097,168. The trade was a 11.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, with a total value of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE lifted its position in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares during the period. Alyeska Investment Group L.P. bought a new position in shares of Sensei Biotherapeutics during the 2nd quarter worth about $3,610,000. Renaissance Technologies LLC boosted its position in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Sensei Biotherapeutics during the 1st quarter valued at about $4,188,000. Finally, Vivo Capital LLC bought a new stake in Sensei Biotherapeutics in the first quarter valued at about $22,758,000. 10.50% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.